Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients

The occurrence of chemotherapy-induced alterations in markers of haemostasis during chemotherapy has been reported previously. However, the change of the haemostasis markers in the cyclophosphamide, epirubicin and fluorouracil (CEF) regimen remains unclear. The aim of the present study was to identi...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2015-09, Vol.3 (5), p.1088-1092
Main Authors: WANG, ZHI, DANG, CHENGXUE, ZHU, KUN, ZHANG, YONG, CHANG, DONGMIN, XIA, PENG, SONG, YONGCHUN, LI, KANG
Format: Article
Language:English
Subjects:
Anticoagulants
Breast cancer
Cancer therapies
Chemotherapy
Clinical trials
Confidence intervals
Cyclophosphamide
D-dimer
deep vein thrombosis
Drug therapy
Epirubicin
fluorouracil
Genetic aspects
Health aspects
Health risk assessment
Hypotheses
Laboratories
Medical prognosis
Oncology
Studies
Thrombosis
Variance analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The occurrence of chemotherapy-induced alterations in markers of haemostasis during chemotherapy has been reported previously. However, the change of the haemostasis markers in the cyclophosphamide, epirubicin and fluorouracil (CEF) regimen remains unclear. The aim of the present study was to identify the change of the haemostasis markers during systemic chemotherapy (600 mg/m2 cyclophosphamide, 80 mg/m2 epirubicin and 500 mg/m2 fluorouracil; four courses over 21 days) to investigate its influence on the haemostasis markers of breast cancer patients and to discuss the requirement of anticoagulation therapy. D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT) and fibrinogen (FIB) values were obtained before chemotherapy and on days 1, 4, 7 and 21. The results show that PT, D-dimer and FIB were not prolonged prior to chemotherapy compared to that under the control. APTT was prolonged until day 4. The levels of D-dimer and APTT were significantly higher compared to those of the breast cancer patients before receiving chemotherapy and controls on days 1, 4, 7 and 21 after chemotherapy. Alteration of the haemostasis markers occurred in the breast cancer patients under the CEF chemotherapy regimen. As there is an increased risk of deep vein thrombosis and pool prognosis of cancer patients, anticoagulant therapy should be considered.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2015.584